IFNA1 and neoplasm: Therefore, reducing the amount of type I IFN in the tumor produced by the virus, employing checkpoint inhibitors to counteract the residual IFN-induced effects on the CAR T cells, and modifying treatment scheduling, may enable combination therapy.